Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02650024 · ClinicalTrials.gov registry record
Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
A clinical trial, sponsored by University of California, San Diego.
- Completed
- Registry status
- 16
- Enrollment target
NCT02650024: Completed study, sponsored by University of California, San Diego.
NCT02650024 is a clinical trial that has completed, run by University of California, San Diego. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02650024 has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV). The goals of this study are to determine the CNS impact of curing chronic HCV disease with newly established DAA therapies and how HIV alters this relationship.
Primary Outcome
Neurocognitive impairment, defined as GDS \> or equal to 0.35, will be tested using a battery of tests covering 7 neurocognitive ability domains that include verbal fluency, information processing speed, learning, memory, executive functions, attention and working memory, fine motor skills.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-01 |
| Est. Completion | 2021-04 |
What the finished NCT02650024 record still lists
NCT02650024 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02650024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02650024 about?
NCT02650024 is a clinical study titled "Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes". This study observes the effects of newly developed direct-acting antiviral (DAA) treatments on the central nervous system (CNS) of individuals with chronic Hepatitis C (HCV). The goals of this study are to determine the CNS impact of curing chronic HCV disease with newly established DAA therapies an...
What is the current status of trial NCT02650024?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2016-01. Estimated completion is 2021-04.
Who is sponsoring clinical trial NCT02650024?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia